BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaoutari AE, Fraunhoffer NA, Hoare O, Teyssedou C, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Dusetti N, Iovanna J. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. EBioMedicine 2021;66:103332. [PMID: 33862584 DOI: 10.1016/j.ebiom.2021.103332] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao R, Ren S, Li C, Guo K, Lu Z, Tian L, He J, Zhang K, Cao Y, Liu S, Li D, Wang Z. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Cancer Med 2022. [PMID: 36161527 DOI: 10.1002/cam4.5296] [Reference Citation Analysis]
2 Fraunhoffer NA, Abuelafia AM, Bigonnet M, Gayet O, Roques J, Nicolle R, Lomberk G, Urrutia R, Dusetti N, Iovanna J. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. NPJ Precis Oncol 2022;6:57. [PMID: 35978026 DOI: 10.1038/s41698-022-00299-z] [Reference Citation Analysis]
3 Gonçalves AC, Richiardone E, Jorge J, Polónia B, Xavier CPR, Salaroglio IC, Riganti C, Vasconcelos MH, Corbet C, Sarmento-Ribeiro AB. Impact of cancer metabolism on therapy resistance - Clinical implications. Drug Resist Updat 2021;:100797. [PMID: 34955385 DOI: 10.1016/j.drup.2021.100797] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
4 Miller AL, Garcia PL, Fehling SC, Gamblin TL, Vance RB, Council LN, Chen D, Yang ES, van Waardenburg RCAM, Yoon KJ. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers (Basel) 2021;13:3470. [PMID: 34298684 DOI: 10.3390/cancers13143470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]